Primary Care

OASIS 1

Study

OASIS 2

Study

OASIS-4

Study

OASIS-5

Study

Obesity

Finding

Obesity

Disease

Obesity hypoventilation syndrome

Disease

Obsessive-compulsive disorder

Disease

OCEAN(a)-DOSE (olpasiran 10 mg)

Study

OCEAN(a)-DOSE (olpasiran 225 mg every 12 weeks)

Study

OCEAN(a)-DOSE (olpasiran 225 mg every 24 weeks)

Study

OCEAN(a)-DOSE (olpasiran 75 mg)

Study

OCEANIC-AF

Study

OCTIVUS

Study

OCTOBER

Study

ODYSSEY

Study

ODYSSEY OUTCOMES

Study

Olmesartan

Drug

Olmesartan / hydrochlorothiazide

Drug

Olopatadine

Drug

Olopatadine / mometasone

Drug

OLV in Thoracic Anesthesia

Study

OLYMPIA 1

Study

OLYMPIA 2

Study

OlympiAD

Study

OMAN

Study

ONTARGET (telmisartan with ramipril)

Study

ONTARGET (telmisartan)

Study

ONWARDS 1

Study

ONWARDS 3

Study

Onychomycosis

Disease

Open-angle glaucoma

Disease

Opioid use disorder

Disease

Opioids for pain

Disease

OPTIMAS

Study

OPTIMUM (micro-US vs. MRI/US)

Study

OPTION

Study

Oral candidiasis

Disease

Oral GLP-1 (danuglipron 120 mg)

Study

Oral GLP-1 (danuglipron 40 mg)

Study

ORBITA

Study

ORBITA-2

Study

ORCA-2 (cytisinicline for 12 weeks)

Study

ORCA-2 (cytisinicline for 6 weeks)

Study

ORCA-3 (cytisinicline for 12 weeks)

Study

ORCA-3 (cytisinicline for 6 weeks)

Study

ORIGIN n-3 Fatty Acids

Study

ORION-10

Study

ORION-11

Study

Orolabial herpes

Disease

Orthostatic hypotension

Disease

Osteochondritis dissecans

Disease

Osteoporosis in men

Disease

Otitis media with effusion

Disease

Otorrhea

Finding

Otosclerosis

Disease

Ototopical ciprofloxacin and fluocinolone in AOE (ciprofloxacin plus fluocinolone vs. ciprofloxacin)

Study

Ototopical ciprofloxacin and fluocinolone in AOE (ciprofloxacin plus fluocinolone vs. fluocinolone)

Study

OUtMATCH

Study

Ovarian cysts

Disease

Overactive bladder

Disease

Oxy-PICU

Study